A paradigm shift is currently underway on the relationship between cancer treatment markers and therapies. Labyrinthin is a prime example of such a marker because it is a pan-cancer target for adenocarcinomas. This movement supports the idea that we must change our thinking from various cancer types (eg, lung, breast, colon) to "cancer arising" in a given tissue or organ. In doing so, this would further support the efforts toward pan-treatments rather than organ-specific treatments.
Keywords: MCA 44-3A6 antibody; adenocarcinoma; biomarkers; cancer diagnosis; cancer marker; cancer target; labyrinthin; pan-cancer; pan-tumor.
© 2019 Radosevich and Babich.